3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
4
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Colorectal Neoplasms
1290
Pancreatic Neoplasms
818
Carcinoma, Hepatocellular
782
Stomach Neoplasms
753
Rectal Neoplasms
563
Esophageal Neoplasms
450
Colonic Neoplasms
414
Esophageal Squamous Cell Carcinoma
275
Neoplasm Metastasis
263
Cholangiocarcinoma
248
Liver Neoplasms
219
Neoplasms
199
Biliary Tract Neoplasms
179
Adenocarcinoma Of Esophagus
139
Gastrointestinal Stromal Tumors
108
Gallbladder Neoplasms
95
Adenocarcinoma
94
Gastrointestinal Neoplasms
89
Breast Neoplasms
89
Carcinoma, Non-Small-Cell Lung
86
Bile Duct Neoplasms
69
Sarcoma
67
Lung Neoplasms
63
Ovarian Neoplasms
60
Anus Neoplasms
59
Melanoma
54
Uterine Cervical Neoplasms
51
Carcinoma
48
Digestive System Neoplasms
45
Prostatic Neoplasms
39
Interventions
tazemetostat
1
durvalumab
1
brigimadlin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Tertiary Lymphoid Structures
×
Gastrointestinal
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn